Significant Improvement of Quality-of-Life in Patients with Psoriasis

Professor Matthias Augustin presents a study on tildrakizumab, which aimed to improve the well-being of psoriasis patients. The study was unique in measuring well-being as the primary endpoint, using the WHO-5 questionnaire alongside other quality-of-life metrics. One of the results showed that tildrakizumab significantly improves patients’ well-being in patients with moderate-to-severe plague psoriasis.